HCRN-GU15-262
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Learn more:
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Learn more:
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter